CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+16%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$70.4K
Cap. Flow
% of AUM
-0.02%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
244
Closed
13
Top Buys
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.28M |
| 2 |
Tesla
TSLA
|
$2.24M |
| 3 |
Apple
AAPL
|
$2.14M |
| 4 |
Meta Platforms (Facebook)
META
|
$2.1M |
| 5 |
Vaxcyte
PCVX
|
$2M |
Top Sells
| 1 |
iQIYI
IQ
|
$4.85M |
| 2 |
Amazon
AMZN
|
$4.7M |
| 3 |
Airbnb
ABNB
|
$3.2M |
| 4 |
Analog Devices
ADI
|
$2.94M |
| 5 |
KE Holdings
BEKE
|
$1.93M |
Sector Composition
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
SIGA Technologies
SIGA
$603M
| $4.72K | ﹤0.01% |
934
-55
| -6% | -$278 |
|
377
Xeris Biopharma Holdings
XERS
$1.27B
| $4.71K | ﹤0.01% |
1,799
-43
| -2% | -$113 |
|
378
Wave Life Sciences
WVE
$1.32B
| $4.69K | ﹤0.01% |
1,289
-36
| -3% | -$131 |
|
379
Design Therapeutics
DSGN
$367M
| $4.62K | ﹤0.01% |
733
-25
| -3% | -$158 |
|
|
BLUE
380
DELISTED
bluebird bio
BLUE
| $4.59K | ﹤0.01% |
70
| – | – |
|
381
Omeros
OMER
$284M
| $4.48K | ﹤0.01% |
824
-26
| -3% | -$141 |
|
382
Monte Rosa Therapeutics
GLUE
$305M
| $4.43K | ﹤0.01% |
647
-9
| -1% | -$62 |
|
383
MacroGenics
MGNX
$126M
| $4.34K | ﹤0.01% |
811
-22
| -3% | -$118 |
|
|
CNTA
384
Centessa Pharmaceuticals
CNTA
$2.11B
| $4.28K | ﹤0.01% |
691
-21
| -3% | -$130 |
|
|
KLRS
385
Kalaris Therapeutics, Inc. Common Stock
KLRS
$86.4M
| $4.17K | ﹤0.01% |
53
-2
| -4% | -$157 |
|
386
Atea Pharmaceuticals
AVIR
$267M
| $4.09K | ﹤0.01% |
1,093
-36
| -3% | -$135 |
|
|
OMGA
387
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $4.04K | ﹤0.01% |
721
-25
| -3% | -$140 |
|
388
ALX Oncology
ALXO
$65.3M
| $4.03K | ﹤0.01% |
536
-16
| -3% | -$120 |
|
|
NIU
389
Niu Technologies
NIU
$338M
| $3.98K | ﹤0.01% |
1,000
| – | – |
|
390
Immuneering
IMRX
$229M
| $3.88K | ﹤0.01% |
383
+25
| +7% | +$254 |
|
391
Humacyte
HUMA
$226M
| $3.88K | ﹤0.01% |
1,355
-43
| -3% | -$123 |
|
392
Foghorn Therapeutics
FHTX
$326M
| $3.86K | ﹤0.01% |
548
-18
| -3% | -$127 |
|
393
Precigen
PGEN
$1.3B
| $3.85K | ﹤0.01% |
3,349
-52
| -2% | -$60 |
|
394
Tango Therapeutics
TNGX
$772M
| $3.85K | ﹤0.01% |
1,158
-37
| -3% | -$123 |
|
395
PMV Pharmaceuticals
PMVP
$77.4M
| $3.76K | ﹤0.01% |
600
-18
| -3% | -$113 |
|
396
ATAI Life Sciences
ATAI
$980M
| $3.74K | ﹤0.01% |
2,175
-73
| -3% | -$126 |
|
397
Sutro Biopharma
STRO
$89.9M
| $3.68K | ﹤0.01% |
792
+13
| +2% | +$60 |
|
398
Phibro Animal Health
PAHC
$1.6B
| $3.66K | ﹤0.01% |
267
-9
| -3% | -$123 |
|
|
IGMS
399
DELISTED
IGM Biosciences
IGMS
| $3.57K | ﹤0.01% |
387
-8
| -2% | -$74 |
|
400
FibroGen
FGEN
$48.9M
| $3.45K | ﹤0.01% |
51
| – | – |
|